| Name | Title | Contact Details |
|---|---|---|
Danilo Guy |
Director of IT Service Management | Profile |
Maureen McLaughlin |
Director of Information Technology | Profile |
Memorial Hospital is a proud part of University of Colorado Health, recognized as a national leader in quality and research. At the local level, Memorial provides a comprehensive list of inpatient and outpatient services at two hospitals and multiple outpatient locations. Memorial provides state-of-the-art, compassionate care in fields such as cardiology, neurology and oncology.
HCI Hospital TV is a Loveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RegenScientific, a wholly-owned business unit of Cytophil, Inc., an ISO 13485 certified company, is dedicated to providing physicians and patients with high-quality, safe, efficacious, and cost-effective soft tissue augmentation implants. The company has CE-Mark for its Renú® Soft Tissue (Volumizing) Implant for lipoatrophy, vocal fold insufficiency, and soft tissue augmentation in Europe. The Company has FDA 510k clearances for its Renú® Gel and Renú® Voice otolaryngology products indicated for vocal fold injection augmentation. Renú® is a registered trademark of Cytophil, Inc. REGENSCIENTIFIC™ and the REGENSCIENTIFIC logo are trademarks of Cytophil, Inc.
ForeverGreen Worldwide Corporation develops, manufactures and distributes an expansive line of all natural whole foods and products to North America, Australia, Europe, Asia, Africa and South America, including their new global Xpress offering Prodigy-5. Additional products include PowerStrips, SolarStrips and BeautyStrips. They also offer their North America weight-management line Ketopia, along with FrequenSea, a whole-food beverage with industry exclusive marine phytoplankton, immune support and weight management products, and Pulse-8 powdered L-arginine formula.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China. Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using our unique dual development approach.